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Abstract
The BRCA Challenge is a long-term data-sharing project initiated within the Global Alliance for
Genomics and Health (GA4GH) to aggregate BRCA1 and BRCA2 data to support highly col-
laborative research activities. Its goal is to generate an informed and current understanding of
the impact of genetic variation on cancer risk across the iconic cancer predisposition genes,
BRCA1 and BRCA2. Initially, reported variants in BRCA1 and BRCA2 available from public
databases were integrated into a single, newly created site, www.brcaexchange.org. The pur-
pose of the BRCA Exchange is to provide the community with a reliable and easily accessible
record of variants interpreted for a high-penetrance phenotype. More than 20,000 variants
have been aggregated, three times the number found in the next-largest public database at
the project’s outset, of which approximately 7,250 have expert classifications. The data set is
based on shared information from existing clinical databases—Breast Cancer Information
Core (BIC), ClinVar, and the Leiden Open Variation Database (LOVD)—as well as population
databases, all linked to a single point of access. The BRCA Challenge has brought together
the existing international Evidence-based Network for the Interpretation of Germline Mutant
Alleles (ENIGMA) consortium expert panel, along with expert clinicians, diagnosticians,
researchers, and database providers, all with a common goal of advancing our understanding
of BRCA1 and BRCA2 variation. Ongoing work includes direct contact with national centers
with access to BRCA1 and BRCA2 diagnostic data to encourage data sharing, development
of methods suitable for extraction of genetic variation at the level of individual laboratory
reports, and engagement with participant communities to enable a more comprehensive
understanding of the clinical significance of genetic variation in BRCA1 and BRCA2.
Author summary
The goal of this study and paper has been to develop an international resource to generate
an informed and current understanding of the impact of genetic variation on cancer risk
across the cancer predisposition genes, BRCA1 and BRCA2. Reported variants in BRCA1
and BRCA2 available from public databases were integrated into a single, newly created
site, www.brcaexchange.org, to provide a reliable and easily accessible record of variants
interpreted for a high-penetrance phenotype.
Introduction
Over 60 years ago, geneticists began to correlate cytogenetic observations with clinical signifi-
cance. Over time, a succession of new genomic technologies has enabled investigators to
BRCA Challenge
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007752 December 26, 2018 2 / 17
Que´bec, and the Canadian Institutes of Health
Research (fund #141210), (http://www.p3g.org/
resources/can-share), BC and MJG are
supported by awards 5U24CA180951-05 and
5U24CA210974-02 from the National Cancer
Institute’s ITCR program (https://itcr.cancer.gov/),
BC-D is supported by R01 HG 008918 “Building
the Medical Information Commons” from the
National Human Genome Research Institute
(genome.gov), BP and MC are supported by grant
U54HG007990 from the National Human Genome
Research Institute (genome.gov), GR is supported
by ETH Zurich (core) funding, JB is supported by
an educational grant from AstraZeneca, HLR is
supported by ClinGen grant U41HG006834 (www.
clinicalgenome.org), MR is supported by the
Breast Cancer Research Foundation (https://www.
bcrf.org/) and an MSKCC Cancer Center Support
grant/Core grant P30 CA008748 (https://www.
mskcc.org/), RGL is supported by grant
U24CA210999 from the National Cancer Institute
(cancer.gov) and grant U01HG008676 from the
National Human Genome Research Institute
(genome.gov), SD is supported by the Basser
Center for BRCA (Philadelphia, PA), SEP is
supported by grant 1U41HG009649, and WDF is
supported by FDN-148390 from Canadian
Institutes of Health Research (http://www.cihr-irsc.
gc.ca). The funders had no role in the preparation
of the article.
Competing interests: I have read the journal’s
policy and have the following conflicts: SEP is a
member of the Scientific Advisory Board of Baylor
Genetics, and is on the editorial board of PLOS
Genetics. MR receives advisory fees, travel fees,
and honoraria from AstraZeneca. The other authors
have no competing interests to declare.
interrogate single-base sequence analyses in clinically informative settings. This led to the
emergence of molecular diagnostics, which, in turn, prompted the development of variant
databases curated by academic and/or national groups. McKusick’s classic textbook evolved
into Online Mendelian Inheritance in Man (OMIM; https://omim.org/), whereas a number of
international efforts were launched to standardize nomenclature and classification—such as
the Human Genome Organization (http://www.hugo-international.org/), Orphanet (www.
orpha.net), the Human Genome Variation Society (HGVS; www.hgvs.org), and the Human
Variome Project (HVP)[1]—as well as reference databases, including the Human Gene Muta-
tion Database (HGMD) (http://www.hgmd.cf.ac.uk/), DatabasE of genomiC varIation and
Phenotype in Humans using Ensembl Resources (DECIPHER; https://decipher.sanger.ac.uk/),
Leiden Open Variation Database (LOVD; www.lovd.nl), and ClinVar (https://www.ncbi.nlm.
nih.gov/clinvar/). Over the last decade, the expansion of next-generation sequencing and its
deployment in routine diagnosis have made variant interpretation a critical rate-limiting factor
in the realization of clinical benefit.
At the first partner meeting of the Global Alliance for Genomics and Health (GA4GH) in
2014, it was agreed to focus one of its demonstration projects on the problem of variant cap-
ture and interpretation, drawing on both traditional clinical resources and the availability of
“big data” to illuminate normal variation. The genes BRCA1 and BRCA2 were chosen because
of their iconic status in the public consciousness and the scale of routine use of genetic test
results to guide major clinical decisions. At the recent launch of the restructured GA4GH,
“GA4GH Connect” [2], BRCA Challenge was identified as one of the inaugural driver projects
for an international effort to enable more robust genomic data sharing in the future. As of
October 2017, it has been relaunched as an independent effort and is working with GA4GH to
engage in the strategic development and uptake of data sharing frameworks and standards.
From the outset, the BRCA Challenge has convened a spectrum of stakeholders to accurately
interpret BRCA1 and BRCA2 variation, to make this information freely available worldwide,
and to improve the care of patients who present with variants in BRCA1 or BRCA2 (Box 1).
Inherited variation in the BRCA1 and BRCA2 genes can indicate genetic predisposition to
breast, ovarian, and other cancers, but a large proportion of observed variants are not disease
associated ("pathogenic")[3, 4]. In response to the need for an international solution to provide
Box 1. Specific goals of the BRCA Challenge
1. Share BRCA1 and BRCA2 variants publicly.
2. Create an online environment for collaborative variant curation with access to evi-
dence (e.g., phenotypes, family history, genetic data, and functional studies).
3. Create a curated list of BRCA1 and BRCA2 variants, interpreted by expert consen-
sus, to serve as a reference for accurate clinical care based on criteria established
by the ENIGMA consortium.
4. Address social, ethical, and legal challenges to global data sharing, and engage with
patient advocacy organizations from around the world.
5. Create a model system for data sharing for other disease genes.
BRCA Challenge
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a comprehensive annotation of BRCA1 and BRCA2 variants, we have developed the BRCA
Exchange—a single comprehensive portal to display global BRCA variation, linking current
structures and resources while encouraging deposition of new data. The BRCA Exchange is
based on shared data from clinicians, clinical laboratories, and researchers across the world,
including existing clinical databases—Breast Cancer Information Core (BIC), ClinVar, and
LOVD—linked to a single point of access. An international interpretation community includes
the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)
consortium [5], established to investigate the clinical significance of variants in breast−ovarian
cancer predisposition genes, and which is recognized by Clinical Genome Resource (ClinGen)
as an expert panel for interpretation of BRCA1 and BRCA2 variants. The purpose of the
Exchange is to provide the community with a reliable and easily accessible record of variants
interpreted as pathogenic for a high penetrance phenotype; the Exchange also reports on vari-
ants deemed “not clinically relevant” (nonpathogenic) and eventually will report on reduced
penetrance variants associated with a moderate or modest risk for a spectrum of cancers (such
as BRCA2 p.K3326�)[6].
The challenge of interpreting BRCA1 and BRCA2 variants
In 1866, the French physician Paul Broca described a cluster of breast cancers in his wife’s fam-
ily, heralding the concept of familial risk for breast cancer [7]. The concept of a cancer-predis-
position gene emerged as a critical driving force for applying the evolving tools of genetic
analyses to map cancer genes in families presenting with breast and/or ovarian cancer; this view
emerged over decades of studies describing familial clusters, twin studies, and special popula-
tions at high risk for breast and ovarian cancer. In 1990, what is now known as BRCA1 was
localized to the long arm of chromosome 17 through analyses of high-risk families [8]. Four
years later, positional cloning and mutational analyses identified the gene itself and revealed
specific coding variants (predominantly truncating alleles) strongly linked to risk for breast and
ovarian cancers within families and high-risk populations [9]. A second major cancer gene for
breast and ovarian cancer, BRCA2, was localized to the long arm of chromosome 13 in 1994
and cloned and sequenced in 1995 [10–12]. By 1996, genetic testing of these two genes was
introduced into clinical practice. Although millions of women, and more recently men, at risk
for cancer have been tested for germline genetic variants in BRCA1 and BRCA2, diagnostic
sequencing has continued to identify variants with uncertain relevance to cancer risk. This has
emerged as a particularly challenging issue for determination of risk for not only breast and
ovarian cancer but now aggressive prostate and pancreatic cancers. What has emerged is that
whereas some germline variants confer high risk for cancer due to disruption of gene function
[13, 14], many BRCA1 and BRCA2 variants identified during routine genetic testing are deter-
mined to have little or no clinical significance with respect to cancer risk [4, 15, 16].
Despite the low overall prior probability of pathogenicity for a variant of uncertain signifi-
cance in these two genes [4, 17], such variants nevertheless present a clinical challenge in that
they complicate test reporting and medical decision-making for clinicians and patients, and
carriers of “equivocal” variants are more likely to over-interpret their result, seek additional
management, or in some circumstances, receive overtreatment by clinicians outside clinical
genetics [18–20]. There are also BRCA1 and BRCA2 variants that appear to be associated with
a modest or moderate (but still elevated) risk of breast and ovarian cancer, compared with “tra-
ditional” deleterious mutations. The clinical reporting on these variants is often inconsistent
and therefore confusing [6, 21–24].
Over decades of study and sequencing at-risk individuals for these two genes and others, it
has become clear that there is a need for a consistent variant classification scheme that is
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systematically developed, validated, peer-reviewed, and published as authority for use by
diverse stakeholders. Previously, the International Agency for Cancer Research (IARC) [25]
and the American College of Medical Genetics and Genomics (ACMG) with the Association
for Molecular Pathology (AMP) [26] proposed schemes for classification of variants as patho-
genic or nonpathogenic, incorporating evidence using quantitative and qualitative approaches.
The utility of these classification efforts has been seen in their incorporation into clinical pipe-
lines, but the practice of interpreting variants remains a daunting challenge. It may be difficult
for individual testing laboratories to have sufficient clinical or laboratory information to assign
classification for rarely encountered variants. Furthermore, the rapid increase in sequence-
based testing, particularly among individuals with no personal or family history of cancer, has
led to more complex variant interpretation. Many sequencing centers have begun to aggregate
observed variants in databases and to classify them using clinical information and variant-level
evidence from multiple sources—thereby reducing uncertainty. However, even between large
laboratories, discordant reporting of variant interpretations continues due to the balkanization
of evidence and differences between curators in utilization of “standard” classification criteria
and/or publicly available evidence [27].
The ENIGMA consortium (http://www.enigmaconsortium.org) is an international multi-
disciplinary consortium [5], currently comprising more than 300 listed members from over
190 research groups and/or clinical testing laboratories spanning more than 35 countries. The
aim of the ENIGMA consortium is to develop methods for improved classification of variants
in BRCA1 and BRCA2 and other known or suspected breast cancer predisposition genes to
guide their use in clinical testing panels. The National Institutes of Health (NIH)-funded
ClinGen (https://www.clinicalgenome.org/) has a process to appoint expert panels to provide
expert variant curation for specific genes. The ENIGMA consortium was approved as an
expert panel by ClinGen to apply its methods to define more precise criteria for annotation of
variants in BRCA1 and BRCA2.
It is anticipated that the number of variants of uncertain clinical significance (VUSs) and
differences in interpretation of the same variant between different laboratories should decrease
with time as public databases approach a fully comprehensive annotation of variants in familial
and population-based settings together with availability of the associated information relevant
to variant classification. It is the express purpose of the BRCA Challenge project and the
BRCA Exchange website to accelerate this process, using BRCA1 and BRCA2 as demonstration
genes. In this regard, interpretation of currently identified VUSs can be accelerated by
enabling increased sharing of existing variant information and using the additional observa-
tions to improve evidence-based classification. Unfortunately, the willingness to share varies
among data holders for a variety of reasons, including ethical and legal challenges with respect
to sharing patient information, resource limitations, and commercial and national health sys-
tem models commodifying patient and variant data. Databases often aggregate incompletely
curated variant classifications with little or no supporting evidence, further muddying the
waters of appropriate interpretation and clinical care.
To date, the scope of BRCA1 and BRCA2 testing has been substantially larger than any
other cancer predisposition gene, yet the ability to look across the spectrum of publicly avail-
able data has not been coordinated. The emergence of multiple public and private databases
worldwide, together with proprietary diagnostic testing databases, have retarded efforts to link
a large set of well-annotated variants for public interpretation. The rapid rise of next-genera-
tion sequencing by academic centers, commercial diagnostic companies, and national pro-
grams has created an additional opportunity to collect information—especially variants
derived from non-BRCA1 and BRCA2 familial cases—and use these to classify more variants.
Together, these factors underscore how BRCA1 and BRCA2 are a compelling case for sharing
BRCA Challenge
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data to advance the precision of variant interpretation, thus enabling clinicians and patients to
make important decisions together.
Development of a public portal for BRCA1 and BRCA2 variants: BRCA
Exchange
The BRCA Challenge has developed an open-access web portal, the BRCA Exchange (http://
brcaexchange.org), a resource to display BRCA1 and BRCA2 variants drawn from global
sources and to enable BRCA1 and BRCA2 variants to be expert-reviewed, interpreted, classi-
fied, and aggregated in an integrated data system (Fig 1). The publicly accessible display of
these classifications, with supporting evidence, facilitates accurate understanding of the clinical
relevance of any individual BRCA1 or BRCA2 variant. The portal is fully open access and
enables easy download of variants and variant-level evidence by anyone with an internet con-
nection. The global focus of the portal enables coordination and collaboration with relevant
investigators and databases from around the world in a supranational consortium, thus
Fig 1. Data flow in the BRCA Exchange pipeline. BRCA Exchange combines information from major public sources to offer a comprehensive view of BRCA
variants from a single web portal. It combines variant information from ClinVar, ENIGMA (as the ClinGen expert panel on BRCA variation) and LOVD (blue);
population frequency data from 1000 Genomes, ExAC, and the ESP (red); and BRCA-specific information from the BIC on BRCA 1 and 2 Ex-UV (green). Each
month, BRCA Exchange collects variant data from these sources and translates them into a consistent representation. It verifies that all variants are consistent in the
reference bases with the reference human genome and discards any variant data that are inconsistent with the genome. Next, it identifies functionally equivalent
variants, in which two or more variants might produce the same alternative allele despite distinct representation, and merges equivalencies to generate a set of distinct
BRCA variants. It gathers annotations, such as functional impact terms and alternative variant names. Finally, it compares the new variant data to the previous month
to identify any variants that are new or updated. These data are shared publicly at brcaexchange.org. The ENIGMA consortium analyzes these aggregated data to
determine the clinical significance of unreviewed variants and deposits these interpretations in ClinVar, completing the cycle of information. BIC, Breast Cancer
Information Core; ENIGMA, Evidence-based Network for the Interpretation of Germline Mutant Alleles; ESP, Exome Sequencing Project; ExAC, Exome
Aggregation Consortium; BRCA Ex-UV, BRCA1 and BRCA2 Ex-UV; GRCh38, Genome Reference Consortium Human Build 38 Organism; LOVD, Leiden Open
Variation Database; TCGA, The Cancer Genome Atlas; TSV, Tab Separated Values; VCF, Variant Format Call; XML, Extensible Markup Language.
https://doi.org/10.1371/journal.pgen.1007752.g001
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creating the most comprehensive source of variation in BRCA1 and BRCA2, including high-
quality variant classifications made by ENIGMA.
To ensure broad usage of the BRCA Exchange, features have been added to maximize utility
of the data. The default view displays only expert-curated variant classifications, in order to
support layperson engagement with the data. Users who wish to access more extensive data
can click through a disclaimer and arrive at a version of the portal that displays the full data-
base, inclusive of classifications made by LOVD and ClinVar submitters and curators other
than ENIGMA, with potential interpretation conflicts. Data quality is ensured by the back-end
pipeline, which merges equivalent variants and filters out variants with erroneous nomencla-
ture terms or reference bases that are inconsistent with the current reference genome. These
data can be downloaded in full and are available for third-party use. The Exchange data are
also versioned with each new data upload, in line with regulations for clinical-grade databases.
The BRCA1 and BRCA2 variant data set comprises data from participating groups and
major academic data sources, including ClinVar (with diverse submitters such as academic
groups, commercial and hospital laboratories, and consortia such as the Consortium of Inves-
tigators of Modifiers of BRCA1/2 [CIMBA] [28, 29]), BIC (also represented in ClinVar) [30],
Exome Aggregation Consortium (ExAC)/Genome Aggregation Database (gnomAD) [16], the
1000 Genomes Project, [31] the BRCA1 and BRCA2 Ex-UV Database displaying classifications
based on multifactorial likelihood analysis [32], LOVD [33], NHLBI GO Exome Sequencing
Project (ESP) [34], and the ENIGMA consortium [5]. Currently, the BRCA Exchange displays
over 20,000 unique BRCA1 and BRCA2 variants; more than 6,100 of those variants are dis-
played with expert classifications from the ENIGMA Consortiumand to date approximately
3,700 have been deemed pathogenic. Variant numbers currently contributed by ClinVar,
LOVD, and the three population frequency databases (ExAC, 1000 Genomes, and ESP) are
shown in Fig 2, with unique and overlapping variants across those data repositories also indi-
cated. Currently, the BRCA Exchange is the most comprehensive, publicly available represen-
tation of BRCA1 and BRCA2 variant information.
Ongoing work is focused on integration of new data and further annotation of the large set
of VUSs; it is estimated that perhaps 80% to 85% of VUSs will ultimately be judged as non-
pathogenic [4, 16], but large-scale aggregation of data is required to support this assertion [3–
5, 17, 35]. To ensure the fidelity of the aggregated data, we filter the input data to ensure that
the variants are consistent with the reference genome and are expressed in correct HGVS
nomenclature. We address duplication in the genomic data by identifying and merging vari-
ants that produce equivalent allele strings. In some cases, we receive data on the same variants
from multiple sources. For example, we receive variant classification data directly from
ENIGMA and BIC and indirectly from these sources via ClinVar. Although these submissions
may represent the same variants, they do not provide exactly the same information for each
variant, and we adapt for this with separate tiles to show the variant attributes specific to each
data source.
We have not yet addressed the issue of noise in the clinical phenotype or other sequence-
unrelated data. One reason is because we intend to show data “as is” from various sources. To
reduce the impact of this noise, the ENIGMA-curated classifications include high-level state-
ments to support the assertions of the classifications. Moving forward, as we begin collecting
individual-level data (see Box 2), it may be possible to assign value judgment on data depend-
ing on the source (e.g., recording discordances with expert-curated variants). Although it will
likely be impractical and unethical to review actual clinical records for the most part, as an
example, we may ask submitters for generic details on the source of their information and note
these accordingly (e.g., self-reported cancer, cancer registry confirmed cancer, and cancer
diagnosis extracted from pathology report provided to submitter).
BRCA Challenge
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We are also exploring ways to avoid duplication of individual-level data because we plan to
move to collection of such data. It is likely that ethical constraints regarding access to identify-
ing information will require specific ethically approved protocols to allow curator access to
identifying information in a secure environment that will allow for crosschecks, such as simi-
larity in pedigree structure, ages, and types of cancer diagnoses. Access to additional accompa-
nying genetic data—in particular, common variation—has utility to detect duplicated or
closely related individuals. Complex pseudoanonymization protocols could prove useful to
access deidentified data with need for individual-level consent (see below), but the issues
around detecting and adjusting for potentially duplicated data points will remain.
In addition to the aggregation of large variant repositories, the BRCA Exchange works with
data sets specific to local populations around the world, especially national initiatives such as
the Brazilian Initiative on Precision Medicine (BIPMed), to support data submission. All
national governments have been approached to encourage participation in the BRCA Chal-
lenge by the United Nations Education, Science and Culture Organization (UNESCO), coordi-
nated by Global Variome (www.humanvariomeproject.org)—an associated nongovernmental
Fig 2. Venn diagram showing variants per large contributing data repositories, with variant overlap between
repositories indicated. Allele frequency databases currently include ExAC, 1000 Genomes, and ESP. ESP, Exome
Sequencing Project; ExAC, Exome Aggregation Consortium; LOVD, Leiden Open Variation Database.
https://doi.org/10.1371/journal.pgen.1007752.g002
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organization, a member of GA4GH, and a partial sponsor of the BRCA Challenge. When pos-
sible, it is recommended that these projects structure data elements for inclusion using the
LOVD open-source software or by direct upload to ClinVar, but it is also possible for these
variant sources to add additional data elements to the Exchange directly in order to capture
the most exhaustive evidence available.
The BRCA Exchange has initiated engagement with patient and advocacy groups, primarily
focusing on getting input from key patient advocates and stakeholders with plans to raise
awareness of the importance of data sharing among global patient and advocate communities
and to encourage patient and advocate groups to engage with data holders to promote sharing
of their data. A further goal is to develop tools to make the database meaningful and useful to
patients and advocates, and to that end, a pilot effort recently released a mobile phone applica-
tion for simple access to the variant database and push notifications when classifications are
updated for variants of interest.
Box 2. Future plans for BRCA Challenge
Toward a comprehensive annotation of genetic variants of BRCA1 and
BRCA2
1. Establish consistency and collaboration in classifications across testing organiza-
tions and local databases
2. Consistent information for BRCA families internationally
3. Global representation of data deposition
4. Use collated individual-level data for developing new classification algorithms
5. Develop safe display solutions for case-level data
Advances for technical development
1. Define a standardized model for international data sharing
2. Develop APIs for distinct shareholders—both internationally and with respect to
laboratory and healthcare providers
3. Pseudonymization software to accelerate annotation of remaining VUS
Outreach
1. Educate country-specific funding bodies on the need to develop a model for feder-
ated funding of data-sharing initiatives
2. Full engagement of patient advocacy
BRCA Challenge
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Technical framework for BRCA Exchange
The BRCA Exchange software has been developed as open-source code found on https://
github.com/BRCAChallenge/brca-exchange/. Technical development has been led by
researchers at University of California, Santa Cruz, and ETH Zurich and hosted on the Micro-
soft Azure cloud. The central component of the BRCA Exchange software is the data analysis
pipeline (Fig 1). Once per month, the automated pipeline downloads variant data from the
ClinVar [36] and LOVD [33] variation repositories, the BIC [30] and BRCA Ex-UV [32]
locus-specific repositories, and the ExAC [37], ESP [34], and 1000 Genomes [31] population
genetics repositories. Additionally, the ENIGMA consortium [5] sends new variant interpreta-
tions to BRCA Exchange when submitted to ClinVar.
After collecting these data, BRCA Exchange determines the GRCh38 (Genome Reference
Consortium Human Build 38 Organism) genomic coordinates of each variant with the HGVS
python library [38] and CrossMap [39]. The pipeline identifies and removes variants with
erroneous genomic representations, such as HGVS strings that are inconsistent with the
HGVS standard and cannot be parsed, or variants for which the reference allele is no longer
consistent with the reference genome. In the most recent release (version 21; July 2018), the
pipeline detected and removed 1,330 erroneous variants. The pipeline then identifies and
merges variants that are genomically equivalent by deriving an alternative allele string for each
variant that consists of the variant plus flanking genomic bases, comparing these allele strings
and merging any variants that yield equivalent allele strings. With this strategy, the pipeline
detects equivalent variants that show no apparent similarity in their HGVS strings or genomic
coordinates, such as complex indels that produce the same alternative allele string through dif-
fering combinations of insertions and deletions. Based on this strategy, sets of variants from
the input repositories are merged into one set of distinct variants. In the most recent release,
the pipeline merged 1,773 pairs of equivalent variants. BRCA Exchange publishes a Docker
container on Dockerhub (https://dockerhub.com) to repeat these processing steps.
The pipeline also computes in silico predictions for each variant to indicate whether the
variant is likely to disrupt splicing, introduce a premature stop codon, and/or impact a key
domain or functional residue (see annotation below). These data are stored in a Postgresql
database, in which they serve the BRCA Exchange web portal, mobile application, and applica-
tion programming interface (API).
As part of this monthly update, BRCA Exchange tracks the update history of each variant.
The update history is displayed in the variant details pages and includes dates of variant data
updates, indications of the specific data updated, and links to download previous versions of
the variant data. In addition to summarizing the changes for each variant, BRCA Exchange
tracks and displays changes to ClinVar and LOVD for each variant to indicate how and when
a clinical or functional interpretation has been updated by its submitter. Users can access ver-
sions of the variant data from any past date, in line with regulations for clinical-grade
databases.
The variant data can be downloaded via the API or web portal. Under the data use policy,
these data can be freely queried, downloaded, reused, and redistributed. The web portal offers
downloads of the latest variant data and all previous data releases since the launch of the proj-
ect. Each data release is distributed as a tarball that contains not just the final variant data but
also the intermediate output files and log files that were generated by the pipeline execution, to
increase the transparency and repeatability of these analysis steps. By using the BRCA
Exchange Docker container published at Dockerhub, a user can replicate the variant merging
and validation portions of the pipeline from this previous data release data for all releases sub-
sequent to February 2018.
BRCA Challenge
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007752 December 26, 2018 10 / 17
To assess the quality of the resulting data, we have compared the expert interpretations from
ENIGMA and consensus classification based on available ClinVar, LOVD, BIC, and ENIGMA
classifications with the variant interpretations from BRCA Share (S1 Table) [40]. BRCA Share is an
independent repository of variants from the Universal Mutation Database (UMD) and the testing
labs Quest Diagnostics and Laboratory Corporation of America (LabCorp). The contents of BRCA
Share are available to academic researchers free of charge and to commercial partners under a sub-
scription fee. We have not yet been able to integrate BRCA Share with the BRCA Exchange vari-
ants due to these differences in the fee structure (the contents of BRCA Exchange are freely
available to all) but we would welcome the opportunity to do so in the future should this issue be
surmounted. As revealed in the comparison, the repositories are largely concordant (S1 Table).
Because the content of these repositories was developed independently, this concordance reflects
favorably on the quality of the data. Each repository contains some variants that are not seen in the
other, and in many cases, offers clinical interpretations of these variants. This point underscores
the value of data sharing, and the potential for additional data sources to provide new knowledge.
Annotation framework: Variant curation and interpretation
The BRCA Exchange seeks to comprehensively gather or compute data for authoritative vari-
ant curation using classification approaches developed by the ENIGMA consortium and to
display these classifications with supporting rationale. The detailed criteria developed by
ENIGMA for BRCA1 and BRCA2 variant classification have been informed by clinically
directed research and are publicly available (http://www.enigmaconsortium.org). These crite-
ria will evolve as new information, including findings from ongoing research, accrues. The
BRCA Exchange resource will incorporate data from many sources, including next generation
sequence data from diagnostic laboratories, and data sets relevant for the ENIGMA variant
classification process that have been collated from publicly available and /or other unpublished
information and curated for accuracy. The key differences of the ENIGMA BRCA1 and
BRCA2 classification criteria to generic classification criteria include the following: both quali-
tative and quantitative (statistically derived) approaches can be applied; variant interpretation
considers a catalog of clinically important protein domains, derived by overlaying extensive
knowledge of protein function and clinical effect of missense alterations; knowledge of natu-
rally occurring mRNA transcripts has been used to inform the interpretation of possible spli-
ceogenic variants; bioinformatic prediction of variant pathogenicity due to alteration at the
level of protein (missense or in-frame deletion) or mRNA transcription (donor, acceptor,
other exonic/intronic sequences like splice enhancers/silencers, and exonic de novo donor
site) have been clinically calibrated for BRCA1 and BRCA2 sequences [16, 32] (Fig 3). It is
notable that reference to population data sets is a key initial step used to parse variants classi-
fied as benign or likely benign because of frequency incompatible with high risk.
Automated processes to prioritize variants within the BRCA Exchange for streamlined clas-
sification and to support the continued curation of variants are under active development,
including calculation of missense alteration prediction scores and prior probability of patho-
genic as well as reference to knowledge of clinically important functional domains. In addition,
variant annotation has been expanded to include automated calculation of splicing prediction
scores and secondary annotation of predicted effects on mRNA splicing. This will include ref-
erence to basic variant position and/or effect annotation to define if a variant leads to gain or
loss of splicing function, assessment of the score relationship to nearest donor or acceptor, as
well as the predicted effect of likely mRNA aberration, e.g., out-of-frame versus in-frame.
These will be made available via the BRCA Exchange and integrated into future versions of the
automated variant annotation process.
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Ethical and regulatory considerations
In collaboration with the GA4GH Regulatory and Ethics Work Stream, the BRCA Exchange
has considered the importance of local as well as global issues surrounding patient data shar-
ing. Recognizing that barriers to data sharing are more than technical, the BRCA Challenge
not only explores technical solutions such as container methods but also receives support and
insight from a highly active Regulatory and Ethics Foundational Work Stream as part of its
relationship as a Driver Project of GA4GH. At the same time, the national context can inform
the use of data and protections required according to local laws and standards, adding com-
plexity to the BRCA Exchange’s goal to aggregate diverse multinational resources. However, it
is possible to develop shared solutions to enable annotated data to be shared widely and better
inform the public as to the significance of specific variants in BRCA1 and BRCA2—some of
which could have widely differing allele frequencies based on population histories.
Sharing can result in extensive benefits through improved clinical care for patients, but it
also brings concerns that public data may be misinterpreted by patients or providers or mis-
used to the detriment of patients [41]. The responsibility to ensure data quality and responsible
use within an online, large-scale data-sharing and curation community such as the BRCA
Challenge needs to be carefully laid out, delegated, and clarified through data submission and
Fig 3. ENIGMA variant classification process. ENIGMA, Evidence-based Network for the Interpretation of Germline Mutant Alleles; ExAC,
Exome Aggregation Consortium; gnomAD, Genome Aggregation Database; HGVS, Human Genome Variation Society; ins-del, insertion-
deletions; UTR, untranslated region; 1000G, 1,000 Genomes Project.
https://doi.org/10.1371/journal.pgen.1007752.g003
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data access and use agreements; for BRCA Exchange, these have been drafted with support
from GA4GH to ensure maximal uptake from global contributors. BRCA Exchange is also pre-
paring materials for genetic counselors as well as nonspecialist physicians and advocacy and
support organizations, as well as considering engagement strategies with such organizations to
enable their participation in design, governance, and oversight. To this end, engagement with
patient advocacy groups has been a central goal—to ensure the community has an accurate
and useful understanding of the public resources. All data were obtained from third-party
sources and no additional ethics approval was required.
As the call for global data sharing increases, it is critical for the BRCA Challenge to develop
strategies to enhance the ability to share variant annotation—and eventually primary data—
through safe and protected mechanisms. One such mechanism is a container software archi-
tecture, in which data can be queried in its home institution, with anonymized and aggregated
results exported. Additionally, the BRCA Challenge supports the use of pseudonymization
software to enable a more comprehensive understanding the clinical significance of genetic
variation in BRCA1 and BRCA2, which, in turn, should lead to reclassification of a fraction of
the current VUSs based on new informative data drawn from disparate sources, including
diagnostic, clinical, and national nodes.
For example, a BRCA Challenge case-level national study is underway involving the
National Cancer Registration and Analysis Service (NCRAS) in Public Health England that
assembles, in near real time, the world’s most detailed clinical data set on all 530,000 cancers
diagnosed by the National Health Service (NHS) each year in the 56 million people of England
and Wales. To date, 14 of the country’s 17 genomic laboratories responsible for BRCA testing
have fully engaged and have uploaded BRCA1 and BRCA2 variant data from over 30,000
patients using in-house open-source pseudonymization software; the irreversible pseudony-
mized reports are matched using NHS Number plus fuzzy matching based on other identifiers.
The pseudonym allows anonymous records derived from the same individual to be linked with-
out the identity of the individual being revealed. Individual clinical data is also encrypted with
its own key and only matching patients’ clinical data is decrypted and made available to the
NCRAS’s cancer registration database. Data is collected by the NCRAS under Regulations 2 and
5 of Section 251 of the NHS Act 2006. The Regulation provides the legal gateway to set aside the
common-law duty of confidence to allow data to be collected without direct consent to support
healthcare functions. This is validated by the local “Caldicott” data guardian at each center. This
approach pioneers the hypothesis-free linkage of molecular variants with electronic patient rec-
ords to build an unbiased prospective knowledge base of cancer predisposition.
Future directions
The BRCA Challenge represents an important step in the sharing and collaborative annotation
of BRCA1 and BRCA2 variants to advance human health globally. The urgent need to develop
stable and comprehensive solutions for sharing data in cancer predisposition and other disease
syndromes has been articulated by many, especially in response to the avalanche of clinical test-
ing underway across the globe [42–45]. Because much of this is not necessarily driven by the
classical paradigms based on familial risk, the BRCA Challenge is positioned to provide a stable,
global solution that accounts for important differences with respect to academic, commercial,
and national interests through the development of tools such as the BRCA Exchange and its cor-
responding mobile application. The BRCA Challenge is positioned to bridge gaps between aca-
demic approaches to variant classification—often conducted in familial collections—with
population-based next-generation sequence data. The inclusion of this latter data source has
begun to alter how and in what context risk for cancer could be estimated.
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For the BRCA Challenge, the first development phase of a mobile application—as part of
the BRCA Exchange—is complete, allowing individuals to track altered classification of vari-
ants. In turn, this information should be useful for clinicians and patients faced with decisions
that will continue to be driven by recommending bodies and the critical relationship between
patient and care provider. Engagement with patient advocacy groups as well as national pro-
grams should provide guidance to refine mobile applications to optimally fit the needs of
many different constituents worldwide. The commitment of the BRCA Challenge to global
data sharing—both for BRCA1 and BRCA2 variants as well as creating a standard applicable to
other genes—can only succeed with involvement of the full spectrum of stakeholders.
As the project progresses, next steps will include collaboration in data aggregation and
interpretation with more global data generators and data holders, continued technical develop-
ment, and increased engagement with patients and patient advocates from around the world
to further this important work (Box 2). With the development of the BRCA Exchange, our
dedicated team has delivered a solution to improve data sharing and variant classification in
the BRCA1 and BRCA2 genes and thus to improve clinical care for clinicians, patients, and
their families. The BRCA Challenge serves as a demonstration project to bring together clini-
cians, researchers, data scientists, patients, and advocates to work toward a new model of data
sharing. Its purpose is to create a comprehensive data-sharing and curation system that could
be easily applied to the more than 114 other cancer predisposition genes identified to date
[46], and ultimately, to all genes underlying recognized disease phenotypes, currently esti-
mated to be around 3,000. In conclusion, the BRCA Challenge is a model for systematically
engaging broad communities and resources for sharing data across genes and eventually regu-
latory regions of major clinical importance.
Supporting information
S1 Table. Comparison of BRCA Exchange to BRCA Share. The BRCA Share [40] repository
contains variants from the UMD and the testing labs Quest Diagnostics and Laboratory Cor-
poration of America (LabCorp). The contents of BRCA Share are available to academic
researchers free of charge and to commercial partners under a subscription fee. To assess
ENIGMA’s concordance with BRCA Share, we analyzed 5,452 variants—most of the BRCA
Share set—by running them through the BRCA Exchange pipeline. BRCA Share contained
3,938 variants not assessed by ENIGMA, and BRCA Exchange contained 4,640 variants that
were assessed by ENIGMA but not found in BRCA Share. In addition, we considered a con-
sensus classification based on available ClinVar, LOVD, BIC, and ENIGMA classifications.
For these consensus classifications, there were 2,228 variants in BRCA Share with no reference
assertion in BRCA Exchange and 13,341 with reference assertions in BRCA Exchange but no
assessment in BRCA Share. We compared the clinical significance assessments of the BRCA
Share variants with the 6,154 assessments from ENIGMA and the 16,565 BRCA Exchange con-
sensus reference interpretations. Overall, the clinical assessments showed a strong similarity.
“Most Neutral” or “Likely Neutral” variants in BRCA Share were assessed as “Benign” or
“Likely Benign” in BRCA Exchange, and most “Causal” or “Likely Causal” variants in BRCA
Share were assessed as “Pathogenic” or “Likely Pathogenic” in BRCA Exchange. The largest
differences were in the VUS counts. BRCA Share contained 310 variants designated as VUS
that were assessed by ENIGMA—296 as “Benign” or “Likely Benign” and 14 as “Pathogenic.”
BRCA Share also contained 473 variants designated VUS that were assessed in BRCA
Exchange consensus—431 as “Benign” or “Likely Benign,” and 42 as “Pathogenic” or “Likely
Pathogenic” (there are also 1,177 variants listed as VUS in both BRCA Share and BRCA
Exchange consensus). In comparison to the number of variant classifications analyzed (5,552
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from BRCA Share, 6,154 from ENIGMA, 16,565 from BRCA Exchange), this represents a high
rate of concordance, which speaks favorably to the overall quality of the public variation data.
Furthermore, the amount of new variant information in BRCA Share, beyond that which is
available in BRCA Exchange, illustrates the potential gains of expanding data-sharing efforts.
BIC, Breast Cancer Information Core; ENIGMA, Evidence-based Network for the Interpreta-
tion of Germline Mutant Alleles; LOVD, Leiden Open Variation Database; UMD, Universal
Mutation Database; VUS, variants of uncertain significance.
(XLSX)
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